These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39232359)

  • 1. A patent review of SCF E3 ligases inhibitors for cancer：Structural design, pharmacological activities and structure-activity relationship.
    Zeng J; Chen Z; He Y; Jiang Z; Zhang Y; Dong Q; Chen L; Deng S; He Z; Li L; Li J; Shi J
    Eur J Med Chem; 2024 Nov; 278():116821. PubMed ID: 39232359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1-F-box interface.
    Gorelik M; Orlicky S; Sartori MA; Tang X; Marcon E; Kurinov I; Greenblatt JF; Tyers M; Moffat J; Sicheri F; Sidhu SS
    Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3527-32. PubMed ID: 26976582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting SCF E3 Ligases for Cancer Therapies.
    Liu J; Peng Y; Zhang J; Long J; Liu J; Wei W
    Adv Exp Med Biol; 2020; 1217():123-146. PubMed ID: 31898226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery.
    Hussain M; Lu Y; Liu YQ; Su K; Zhang J; Liu J; Zhou GB
    Pharmacol Res; 2016 Sep; 111():34-42. PubMed ID: 27238229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
    Kitagawa K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases.
    Zhou W; Wei W; Sun Y
    Cell Res; 2013 May; 23(5):599-619. PubMed ID: 23528706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.
    Xie CM; Wei W; Sun Y
    J Genet Genomics; 2013 Mar; 40(3):97-106. PubMed ID: 23522382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCF E3 ubiquitin ligases as anticancer targets.
    Jia L; Sun Y
    Curr Cancer Drug Targets; 2011 Mar; 11(3):347-56. PubMed ID: 21247385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
    Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
    Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Structure-Based Strategy for Engineering Selective Ubiquitin Variant Inhibitors of Skp1-Cul1-F-Box Ubiquitin Ligases.
    Gorelik M; Manczyk N; Pavlenco A; Kurinov I; Sidhu SS; Sicheri F
    Structure; 2018 Sep; 26(9):1226-1236.e3. PubMed ID: 30033217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
    Yu Q; Xiong X; Sun Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
    Chan CH; Morrow JK; Li CF; Gao Y; Jin G; Moten A; Stagg LJ; Ladbury JE; Cai Z; Xu D; Logothetis CJ; Hung MC; Zhang S; Lin HK
    Cell; 2013 Aug; 154(3):556-68. PubMed ID: 23911321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of SCF ubiquitin-ligase complex at the beginning of life.
    Xie J; Jin Y; Wang G
    Reprod Biol Endocrinol; 2019 Nov; 17(1):101. PubMed ID: 31779633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAG/ROC-SCF beta-TrCP E3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection.
    Tan M; Gallegos JR; Gu Q; Huang Y; Li J; Jin Y; Lu H; Sun Y
    Neoplasia; 2006 Dec; 8(12):1042-54. PubMed ID: 17217622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate.
    Bornstein G; Ganoth D; Hershko A
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11515-20. PubMed ID: 16861300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
    Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein.
    Lyapina SA; Correll CC; Kipreos ET; Deshaies RJ
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7451-6. PubMed ID: 9636170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation.
    Wu K; Fuchs SY; Chen A; Tan P; Gomez C; Ronai Z; Pan ZQ
    Mol Cell Biol; 2000 Feb; 20(4):1382-93. PubMed ID: 10648623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The characteristics and roles of β-TrCP1/2 in carcinogenesis.
    Bi Y; Cui D; Xiong X; Zhao Y
    FEBS J; 2021 Jun; 288(11):3351-3374. PubMed ID: 33021036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.